PHILADELPHIA — The genome sequences of ape parasites related to Plasmodium vivax (P. vivax), the main source of mosquito-borne malaria outside Africa, provide insights on the origin and early evolution of the human parasite. This finding could have implications for better comprehending and eradicating malaria infection worldwide, according to new research from the Perelman School of Medicine at the University of Pennsylvania and the University of Edinburgh, published this week in the Proceedings of the National Academy of Sciences.
While not as deadly as malaria caused by Plasmodium falciparum, P. vivax malaria is debilitating and widespread, potentially infecting about one third of the world’s population, mainly in Asia and Latin America. Most people in Africa are not at risk for infection by P. vivax malaria because they carry a genetic mutation that makes them resistant to this strain. However, African apes living in the wild are naturally infected with parasites that are very similar to those infecting humans. The researchers caution that it is important to monitor new cases of P. vivax infection in central Africa to determine whether any reflect ape-to-human transmissions.
“Chimpanzees, bonobos, and gorillas all harbor parasites that are close relatives of human P. vivax, but to date our knowledge of these parasites has been limited to a small number of gene fragments,” said co-senior author Beatrice Hahn, MD, a professor of Medicine and Microbiology at Penn.
In this study, researchers compared almost-full-length genomes of ape parasites with sequences of P. vivax strains infecting humans worldwide.
“We found that ape and human parasites share near-identical genomes, differing by only two percent within the gene sequences that code for proteins,” said Dorothy Loy, an MD/PhD student in Hahn’s lab.
After generating sequences of parasites infecting chimpanzees and gorillas, the team found that ape P. vivax show very different patterns of genetic diversity, compared to their human counterparts. They also found no evidence that the ape P. vivax parasites discriminate which ape species they infect.
“We discovered that ape parasite strains show about 10 times more genetic diversity compared to their human-infecting counterparts,” said Lindsey Plenderleith, PhD, from the Edinburgh team. This suggests that some time in the past the human parasites underwent a severe reduction in their population size, leading to a massive loss of genetic variation.
From an ancient population of P. vivax parasites, which likely infected both humans and apes in Africa, a “bottlenecked” parasite population emerged when P. vivax migrated with humans out of Africa. This once-small parasite population subsequently underwent a rapid population expansion as it dispersed over much of the globe, while the spread of the malaria-protective mutation eliminated P. vivax from people in most of sub-Saharan Africa.
Based on additional testing of certain P. vivax proteins associated with the parasites’ ability to invade host red blood cells, the team also concluded that it is possible that ape and human strains could infect the same hosts and undergo genetic exchange if their geography overlapped.
Recently, reports of P. vivax infection of humans in Africa have been increasing. “Since parasites very similar to human P. vivax infect a large number of wild-living apes, we need to be aware that there could be spillover into humans,” said co-senior author Paul Sharp, PhD, an evolutionary biologist at the University of Edinburgh. The team cautions that malaria monitoring programs should keep a watch to see if the genetic diversity of the ape parasites is infiltrating human-infecting strains.
This work was supported in part by the National Institutes of Health (R01 AI097137, R01AI091595, R37 AI050529, P30 AI045008); the Agence Nationale de Recherche, an Australian Research Council Future Fellowship and a Howard Hughes Medical Institute - Wellcome Trust International Research Scholar Award.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $425 million awarded in the 2018 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Home Care and Hospice Services, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 40,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2018, Penn Medicine provided more than $525 million to benefit our community.